Gaps in the Continuum of HIV Care: Long Pretreatment Waiting Time between HIV Diagnosis and Antiretroviral Therapy Initiation Leads to Poor Treatment Adherence and Outcomes
Table 2
Predictors of loss to follow-up and HIV-related mortality over the whole study period among eligible participants in the ART observational database of the Yuxi District.
Loss to follow-up
Mortality
Cases/participant, person-years
ARR, value
Cases/participant, person-years
ARR, value
Delayed status
Nondelayed testers
56/1212, 3869
Ref.
103/1315, 3995
Ref.
Delayed testers
12/282, 1129
1.49 (1.30–1.72), <0.01
66/348, 1243
1.43 (0.68–2.26), 0.48
Gender
Female
18/623, 1831
Ref.
38/661, 2038
Ref.
Male
50/871, 3167
1.06 (0.95–1.19), 0.29
131/1002, 3200
1.44 (0.68–3.06), 0.34
Age
68/1494, 4998
1.01 (1.00–1.01), <0.01
169/1663, 5238
1.07 (1.04–1.09), <0.01
Transmission route
Heterosexuals
37/1073, 3226
Ref.
85/1158, 3341
Ref.
IDU
27/282, 1294
1.53 (1.11–2.11), <0.01
70/352, 1368
2.88 (1.34–6.17), <0.01
FPD
0/9, 24
—
0/9, 24
0
MSM
0/44, 99
—
2/46, 100
0.54 (0.07–4.40), 0.57
Unknown
4/86, 355
1.23 (0.83–1.47), 0.19
12/98, 405
2.11 (0.87–2.81), 0.33
Pretreatment waiting time (every 100 days) in nondelayed
56/1212, 3869
1.20 (1.07–1.29), <0.01
103/1315, 3995
1.11 (1.06–1.21), <0.01
Pretreatment CD4 decline (every 100 cells/mm3) in nondelayed
